Paul Berns, President & CEO, Director at Anacor Pharmaceuticals, holds 7.79M shares in Neumora Therapeutics, Inc. (Ticker: NMRA), holds 0.00 shares in Metsera, Inc. (Ticker: MTSR), holds 0.00 shares in EQRx, Inc. (Ticker: EQRX). Most recently, Paul Berns Sold ― shares of Neumora Therapeutics, Inc. on Feb 19, 2026 for an estimated value of $34.37K.
Paul Berns latest transaction was an Informative Sell of $34.37K.
What was Paul Berns's most profitable transaction?
Paul Berns’s most profitable transaction was an Informative Sell of JAZZ stock on August 11, 2015. The return on the trade was 22.70%.
What is Paul Berns's role in Anacor Pharmaceuticals?
Paul Berns's role in Anacor Pharmaceuticals is President & CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.